Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours.

Lise Bentzen, Susanne Keiding, Marianne Nordsmark, Lise Falborg, Søren B Hansen, Johnny Keller, Ole S Nielsen, Jens Overgaard

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;67(3):339-44

PMID: 12865184

Abstract

BACKGROUND AND PURPOSE

The aim of the study was to identify hypoxia in human soft tissue sarcomas (STS) by PET scanning using the hypoxia marker [18F]-fluoromisonidazole ([18F]FMISO) and invasive oxygen sensitive probes (Eppendorf pO2 Histograph, Germany).

MATERIALS AND METHODS

Thirteen patients with tumours suspected to be STS were examined by [18F]FMISO PET scanning, and eleven of these patients completed a set of Eppendorf pO2 Histograph measurements following the scanning.

RESULTS AND DISCUSSION

By histopathological diagnosis, seven tumours were shown to be STS and six tumours were benign. Ratios between tumour and muscle radioactivity and time activity curves for tumours and muscle tissue were examined in defined regions of interest. Only two malignant tumours showed [18F]FMISO uptake in higher amounts than muscle tissue over time. Hypoxia was present in both benign and malignant tumours as measured by the oxygen electrode method.

CONCLUSIONS

[18F]FMISO PET in our setting seemed not to be feasible for the detection of tumour hypoxia in human soft tissue tumours. Neither did it reflect the extent of hypoxia as determined with the oxygen electrode measurements.

Address: Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 4, DK-8000 Aarhus C, Denmark.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.